Anti-Mullerian Hormone (AMH) is a key biomarker in reproductive medicine and reflects ovarian reserve. This essentially reflects the number of eggs remaining in the ovaries. Having low AMH levels does not mean that the person is unable to conceive. Although it implies fewer eggs, it does not necessarily indicate egg quality, or imply that In Vitro Fertilisation (IVF) will be ineffective. Specialised protocols have now been incorporated in modern fertility treatments with a focus on improving the potential of the depleted ovarian reserve.
This article will delve into the connection between AMH and fertility, why pregnancy remains achievable with lower AMH levels, and the different medical approaches that can be taken to enhance IVF results.
The small follicles in the ovaries produce the Anti-Mullerian Hormone. Because these follicles contain immature eggs, the level of AMH in the blood generally correlates with the number of eggs a woman has. A high level typically indicates that the reserve is robust, whereas a low level indicates that the reserve is dwindling.
In fertility, a low AMH value serves as a predictor of the ovaries' response to stimulation in an IVF cycle. It warns experts that the woman may yield fewer eggs during retrieval. It is, however, important to keep in mind that AMH is a quantitative, not a qualitative, measure. A woman with low AMH can still deliver high-quality eggs to result in a healthy pregnancy.
Reduced ovarian reserve is a normal part of ageing. The majority of women also see a dramatic decline in AMH levels during their mid-30s and early 40s. Nonetheless, some younger women can also have low AMH because of early ageing of the ovaries or because of heredity. Studies (ref.) suggest that approximately 10–15% of women undergoing fertility treatment have diminished ovarian reserve. Since this condition can be unaccompanied by any external symptoms, most women only learn of their condition during regular fertility checkups or when they find themselves unable to conceive.
Low AMH levels may also affect the ovaries' response to stimulation during in vitro fertilisation (IVF), but it does not eliminate the chances of success. The major problem in these situations is that the number of eggs retrieved in a treatment cycle is often low, rather than the inability to conceive altogether.
During IVF, hormonal drugs are administered to induce the ovaries to generate several eggs. Women with low AMH may respond less effectively to such drugs, and this leads to fewer follicles and, therefore, fewer eggs available for fertilisation. Still, a few good-quality eggs may still result in pregnancy and embryo development.
Typically, a fertility specialist will customise an IVF protocol for a patient with a low AMH. Some possible adjustments to the IVF cycle based on the individual patient’s profile may include the stimulation protocols: for instance, the increased-dose gonadotropin stimulation or a more gentle, moderate stimulation. Depending on the situation, repeated IVF cycles may be recommended to improve overall success rates.
Age is also a critical factor to consider. Younger women with low AMH can still have good-quality eggs, which can make a huge difference. On the other hand, in women of advanced age, the number and the quality of eggs may be influenced.
Several factors reduce the number of eggs a woman has. Although age is the primary factor in declining fertility, several other possible influences may accelerate this process:
When assessing the effectiveness of IVF, it is necessary to consider AMH and age as two sides of the same coin. Although AMH indicates the number of eggs that can be retrieved, age is the most important indicator of egg quality and chromosomal health. Generally, a younger woman with low AMH will have a better prognosis than an older person with high AMH, simply because the smaller number of eggs retrieved has a higher chance of being genetically normal and thus implanting successfully.
Key considerations for success include:
Some challenges need to be managed for IVF when you are diagnosed with diminished ovarian reserve. The main challenges of such an IVF treatment are
Women with low AMH might not respond well to normal IVF procedures. Rather, experts tend to use either Mini-IVF or Natural Cycle IVF. In these methods, lower doses of stimulation drugs are employed to prevent overstimulation of the few remaining follicles. The idea is to produce two or three high-quality eggs instead of forcing the ovaries to produce a dozen or more of inferior quality.
Another common strategy is "DuoStim" or cycle pooling. This will be done by performing two egg retrievals in one menstrual cycle to harvest enough eggs to produce more than one embryo, followed by a transfer. This enhances the combined likelihood of success.
Fertility specialists focus on the precision and sophisticated laboratory methods to increase the chances of a successful outcome in case of low ovarian reserve. The following are the basic strategies to enhance IVF success with low AMH:
In addition to medication, these laboratory-based techniques will further improve your chances of pregnancy:
Overall physical and mental well-being can enhance the chances of a successful IVF. It will not raise the AMH level, but it will preserve the remaining egg quality:
A fertility journey with low AMH can be challenging, but it is far from hopeless. The key to success in IVF is an individualised approach to medical treatment, innovative laboratory methods, and a shift in focus from the quantity of eggs to the quality of the ova. Learning that AMH is simply a measure of egg count, patients can work with their experts to determine the most effective stimulation protocols and additional treatments. There are several methods available which can help a patient to achieve their family plan, including tailored IVF treatment plans, lifestyle modification and the use of donor eggs. Ultimately, it is all about an early diagnosis and a proactive approach toward reproductive health.